A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma Larynx
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2019
Price : $35 *
At a glance
- Drugs Nelfinavir (Primary)
- Indications Laryngeal cancer; Mouth neoplasm; Pharyngeal neoplasms; Squamous cell cancer
- Focus Therapeutic Use
- 15 Feb 2019 Trial focus and primary end point has been changed from Adverse Reactions to Therapeutic Use.
- 15 Feb 2019 Planned End Date changed from 1 Jul 2019 to 1 Feb 2020.
- 15 Feb 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Nov 2019.